Cambridge, UK - 23rd December 2016
Levrett, a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces its interim results for the period ended 30 September 2016.
Further to the announcement dated 16 September 2016 relating to the possible acquisition of Nuformix Limited, the Company can confirm that the Acquisition is at an advanced stage, subject to the completion of documentation and compliance with all regulatory requirements.
The Company intends to convene a General Meeting in order to seek the shareholder approvals necessary to pursue this opportunity, following publication of the prospectus. Further announcements to shareholders will be made in due course.Download News